• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > About > Annual reports > Annual Report 2021
2021 Asia highlights
Home > About > Annual reports > Annual Report 2021
2021 Asia highlights
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Driving innovation through South-South collaboration

Recent years have seen a revolution in medical innovation for hepatitis C, which can now be cured with just 8 to 24 weeks of safe, simple treatment. But in many low- and middle-income countries (LMICs), treatments are simply priced out of reach, standing in the way of ‘test-and-treat’ strategies that have the potential to eliminate hepatitis C altogether.

Our R&D alliances are proving that another way is possible, as evidenced by recent progress in Southeast Asia.

In 2016, DNDi established an innovative partnership between the Ministry of Health in Malaysia, the Ministry of Public Health in Thailand, Pharco Pharmaceuticals in Egypt, Pharmaniaga in Malaysia, and Médecins Sans Frontières (MSF) to develop ravidasvir for hepatitis C through an alternative R&D pathway centred on patients’ needs and affordability.

In June 2021, the Malaysian National Pharmaceutical Regulatory agency granted conditional approval of ravidasvir as part of an affordable, safe, and highly effective all-oral cure for hepatitis C – the  first developed through South-South collaboration.

DNDi teams are now leveraging our experience joining essential government, science, and industry partners across LMICs to find a safe, effective, and affordable treatment for dengue fever within five years. Dengue is a climate-sensitive disease and growing threat to public health worldwide, but with an estimated 390 million dengue infections each year in more than 100 countries, there is no specific treatment available for the disease.

In 2021, we concluded extensive consultations with partners and dengue experts to establish research priorities, and by early 2022, our first government partners from India, Brazil, Malaysia, and Thailand had joined the new initiative. We look forward to additional partners from other dengue-endemic regions joining soon and to showing how global health R&D coordination, collaboration, and financing can be re-imagined to support a more distributed, decentralized, and democratic approach to the production of knowledge and innovation as global public goods.

In Malaysia, Dr Akhmal Yusof, CEO, Clinical Research Malaysia and Jean-Michel Piedagnel, Director, DNDi Southeast Asia Regional Office signed a new dengue partnership agreement, accompanied by Dr Noor Hisham Abdullah, Director-General of Health, Mr Khairy Jamaluddin, Minister of Health, and Dr Hishamshah Mohd Ibrahim, Deputy Director-General of Health.
With DNDi’s commitment to ensure accessible treatments for neglected communicable diseases, the Ministry of Health of Malaysia looks forward to collaborating with established research institutes from India, Thailand, and Brazil to address gaps in the research and development of new dengue drugs.
Mr Khairy Jamaluddin, Minister of Health, Malaysia

Paving the way for the elimination of visceral leishmaniasis in India

In India, the first cases of kala-azar, or visceral leishmaniasis (VL), were recorded in the area of West Bengal in the mid-1800s. Endemic in the country ever since, major outbreaks of the disease have represented an acute public health challenge. However, thanks to government commitment and partnerships to identify and scale up access to shorter, simpler treatments, elimination of VL as a public health problem in India is now within reach.

Since the start of intensified VL detection and treatment activities in India, VL cases have plummeted by 98%, from 77,100 registered cases in 1992 to just 1,275 in 2021.  However, the ‘last mile’ of India’s push towards VL elimination presents unique challenges, as will sustaining elimination, once achieved. Strengthening access to effective treatments for VL relapse, VL/HIV co-infection, and other complications will be crucial – including for post-kala-azar dermal leishmaniasis (PKDL), which can develop months or years after a person completes VL treatment. While not deadly, PKDL can be disfiguring and stigmatizing and can also act as a reservoir of VL infection, challenging elimination efforts.

Lalmati Devi, 45 years old, lives in Bheldi, Bihar, India. After being diagnosed with post-kala-azar dermal leishmaniasis, she started treatment with miltefosine but faced severe side effects that prevented her from completing treatment.

To support the final stages of India’s VL elimination strategy and safeguard sustainability, DNDi has joined with the National Centre for Vector Borne Diseases Control and the Rajendra Memorial Research Institute to establish VL Centres of Excellence (COEs) at two pilot sites in Bihar that manage complicated VL cases requiring hospitalization and specialized care.

With funding from the Takeda Pharmaceutical Company Limited Global CSR Program, the COEs will train healthcare staff and ensure access to necessary tools to strengthen care for patients with VL, PKDL, and VL/HIV, including appropriate diagnostics and treatments. DNDi teams are also working to support the development of standard operating procedures for managing complicated cases at the COEs, which will act as reference and referral centres that can be replicated as required in other endemic areas.

BACK TO 2021 ANNUAL REPORT

Photo credits: Matt Bouch-DNDi; Black Visuals-DNDi;Manis Gupta-DNDi

Connect and share

Follow us on social media to stay updated and help us share the stories of neglected patients.  

Twitter
Facebook
Instagram
Youtube
Linkedin
EN ESPAÑOL
EM PORTUGUÊS
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo